anical, chemical or immunohistochemical procedures. 4 This results in a decrease of malignant cells with values from 3 up to more than 5 log, 4-6 but does not eradicate malignant CD34-positive cells were isolated from cord blood (n ‫؍‬ 8), bone marrow (n ‫؍‬ 4) and leukapheresed material cells in any case. A more recently applied method is enrichment and reinfusion of hematopoietic stem cells. In humans (n ‫؍‬ 7), using an immunomagnetic isolation technique, MACS (Miltenyi Biotec, Bergisch Gladbach, Germany).
including T cells, granulocytes and thymocytes, is CD44. hematopoietic stem cells express CD44v5 and CD44v6 to a very small extent offers the possibility of using anti-CD44 is known as the hyaluronic acid receptor. 9 A complex genomic organisation with at least 20 exons is responsible bodies specific to CD44v5 and CD44v6 in immunopurging in the course of autologous stem cell transplantation.
for the generation of several splice variants. 8, 10 Until now, 15 different spliced types of CD44 are known. To disKeywords: autologous bone marrow transplantation; CD44 standard receptor (CD44s); CD44 isoforms (CD44v); tinguish between the standard receptor phenotype and spliced phenotypes, the commonly expressed hyaluronic purging methods; hematopoietic stem cell; stem cell enrichment; magnetic cell separation acid receptor was termed CD44s, all splice variants were termed CD44v. 8, 11 All splice variants are longer in size and bear additional extracellular protein domains. The generation of CD44 splice variants seems to be correlated with Autologous bone marrow transplantation is of increasing processes of activation, inflammation and tumor proimportance not only in the therapy of leukemia, but also in gression. [12] [13] [14] [15] Possibly by analogy to its function in lymphothe therapy of solid tumors. The benefit of autologous bone cyte migration, CD44 variant molecules have been shown marrow transplantation is hampered by an elevated risk of to confer metastatic capability on rat tumor cell lines. 16 relapse in the course of bone marrow reconstitution. This Homologues of these variants, especially CD44v5 und relapse may result from malignant cells, which contaminate CD44v6, have been detected in several human maligthe bone marrow to varying extents. [1] [2] [3] nancies including non-Hodgkin's lymphoma, 17 breast, 18 Several strategies exist to prevent cotransplantation of stomach, 19 and colon 20 where they have been reported to malignant tumor cells in autologous transplantation. The be associated with tumor progression and tumor spread as most prominent method of reducing the tumor mass is bone well as with a worse prognosis of patients. marrow purging. Bone marrow cells are subjected to mechGeneration of CD44v5 and CD44v6 is not restricted to metastasizing cells, expression of these splice variants seems to be a general pattern of immune defense. 21 The Enriched target cells from bone marrow, cord blood or leukapheresed material were washed with cold PBS (Gibco). FCS (Hyclone, Cramlington, UK). RPMI 1640 (Biochrom, Berlin, Germany) was applied without any indicator dye.
Cells were resuspended in immunofluorescence buffer, containing 5% Polyglobin N (Troponwerke, Cologne, Cells were washed twice with RPMI 1640. Freshly obtained leukapheresed material and bone marrow samples were Germany) and 0.05% NaN 3 . CD44-specific antibodies (murine, IgG 1 ) were provided by Bender & Co GesmbH washed once using RPMI 1640. To remove clumps the material was digested with 0.02% collagenase (Sigma, (Vienna, Austria). Antibodies used (CD44s (SFF-2), CD44v5 (VFF-8), CD44v6 (VFF18)) were directly biotinDeisenhofen, Germany), type V, and 200 U/ml DNAse (Calbiochem, Bad Soden, Germany). Digestion was carried labeled or fluorochrome-conjugated (FITC). The antibody concentration applied for CD44 isoforms was in the range out for 45-90 min at room temperature, gently shaking the cell suspension. Cells were filtered through a 40 m nylon of 1.0-2.5 g/ml. CD34-/CD44-double fluorescence staining (FITC/PE-or FITC/biotin-labeled antibodies) was percell strainer (Becton Dickinson, San José, CA, USA). For further information on the leukapheresis material used see formed simultaneously using a CD34-specific antibody and the CD44 antibody of choice. Incubation took place at 4°C Table 1 . Bone marrow samples were obtained from healthy donors.
for 30 min in the dark. Cells were washed twice with PBS of CD44-positive and CD44-negative cells were disIn addition, artificial mixing experiments were performed tinguished using dual parameter statistics in a dot plot of (Figures 1 and 2 of CD44v5/CD44v6 Ͻ1%) and the cell line HCT-116, posiIn general low expression of CD44v and high expression tive for CD44 isoforms under investigation (no expression of CD44s was confirmed (Table 2) . of CD34, expression of CD44v5 60%, expression of CD44v6 66%), gave further evidence for the efficacy of Discussion CD44v-specific antibodies used (Figures 1 and 2 While a very strong and ubiquitous expression of CD44s was noted, there were only minor traces of expression of the tumor-associated CD44 variants CD44v5 and CD44v6.
Viability of nonseparated and separated cells
It is widely accepted that CD34 + cells represent, at least to Viability of cells from cord blood, leukapheresis and bone some extent, a pool of hematopoietic stem cells. It must be marrow samples as assessed by means of trypan blue noted that the population of CD34 + cells is heterogeneous exclusion was greater than 98%.
with regard to pluripotency and state of differentiation. CD44s resembles a common marker, found on all types of leukocytes. should be subjected to a second step of immunopurging. 
